Physician profile
Daniel Varela
NPI 1477084176
$4,481.26
in general payments reported to CMS, 2019-2025
25 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $291 · 2023: $1,745 · 2024: $1,108 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,917 · Education: $23.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.07 |
| Education | $23.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $932.50 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $932.40 | 2023-2025 | Rinvoq, Humira, Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $421.01 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $356.32 | 2021-2025 | Saphnelo, Farxiga |
| Amgen INC. | $274.16 | 2023-2025 | Krystexxa, Tavneos, Prolia |
| Radius Health, INC. | $185.23 | 2023-2025 | Tymlos |
| Medtronic, INC. | $160.18 | 2025 | Ellipsys Vascular Access System |
| Aurinia Pharma U.S., INC. | $138.41 | 2021-2023 | Lupkynis |
| Lilly USA, LLC | $130.49 | 2023-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $126.84 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $123.95 | 2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $123.48 | 2025 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $86.35 | 2025 | Opdivo |
| Vifor Pharma, INC. | $79.02 | 2022 | |
| Insulet Corporation | $69.32 | 2023-2024 | Omnipod |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $57.58 | 2023-2024 | Entyvio, Gattex |
| Ardelyx, INC. | $56.33 | 2024 | Ibsrela |
| Madrigal Pharmaceuticals | $49.76 | 2025 | Rezdiffra |
| Travere Therapeutics, INC. | $39.72 | 2023 | |
| Sumitomo Pharma America, INC. | $37.57 | 2024 | Gemtesa |
| Ucb, INC. | $28.10 | 2024 | Bimzelx |
| Calliditas Therapeutics US INC. | $24.81 | 2025 | Tarpeyo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.30 | 2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $15.45 | 2021 | |
| Novo Nordisk INC | $14.98 | 2023 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Varela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.